|Awarded On||November 19, 2015|
|Title||Role of Cohesin in Hematopoiesis and Myeloid Leukemia in Children with Down Syndrome|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Debananda Pati|
Children with Down syndrome (DS) are at an increased risk of developing leukemia. Nearly half of the DS leukemia in children is classified as acute megakaryoblastic leukemia (AMKL), a relatively rare subtype of acute myeloid leukemia (AML) with dismal prognosis - median overall survival is 6 months. A myelodysplastic phase known as transient myeloproliferative disorder (TMD) frequently precedes development of AML in these children, and the spectrum of both myelodysplastic syndrome (MDS) and AML have been known collectively as myeloid leukemia of Down syndrome (ML-DS). Children with ML-DS represent approximately 15% of the pediatric AML cases. Over 95% of ML-DS cases are diagnosed in children...